The Young SLEuro Forum first-ever activity: Research Roundtables at the Lupus Meeting 2026 in Lisbon.
Early-career researchers in SLE met with a Mentor in small groups to discuss scientific ideas and build meaningful connections!
#YoungSLEuroForum#ELM2026
Presented at the 15th European Lupus Meeting:
In patients with SLE without advanced lupus nephritis, obinutuzumab plus standard therapy was superior to placebo plus standard therapy in conferring and sustaining a clinically meaningful reduction in disease activity over 52 weeks. Full phase 3 ALLEGORY trial results: https://t.co/KykhH0rJ3L
#SLEuro | @SLEuroSociety
✅ One unique link for those living with #lupus, to test your essential #SLE knowledge using #SLAKE in any of the following languages ⬇️
https://t.co/oVPRPZpj96
Please note that it is better to do the testing on PC/Mac rather than on mobile phone 👌